This company has been marked as potentially delisted and may not be actively trading. NASDAQ:NGM NGM Biopharmaceuticals (NGM) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About NGM Biopharmaceuticals Stock (NASDAQ:NGM) Get NGM Biopharmaceuticals alerts:Sign Up Key Stats Today's Range$1.54▼$1.5450-Day Range$1.52▼$1.6352-Week Range$0.60▼$4.69VolumeN/AAverage Volume1.47 million shsMarket Capitalization$128.53 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company develops NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced metastatic solid tumors; and Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of primary sclerosing cholangitis and non-alcoholic steatohepatitis. It also develops NGM120, an GFRAL antagonist antibody, which is in Phase II clinical trial to treat hyperemesis gravidarum; NGM831 and NGM438 which is in phase I/II clinical trial for the treatment of advanced solid tumors; and NGM621, an monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck to focus primarily on the identification, research and development of collaboration compounds directed to targets in the fields of ophthalmology and cardiovascular or metabolic, or CVM, disease, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California. Read More Receive NGM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NGM Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NGM Stock News HeadlinesNuvig Therapeutics Appoints David J. Woodhouse, Ph.D., as Chief Executive Officer and James Mackay, Ph.D., as Independent Board ChairSeptember 9, 2025 | finance.yahoo.comXaira Therapeutics Announces the Appointment of Jeff Jonker as President and Chief Operating OfficerJuly 10, 2025 | finance.yahoo.comNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor Green, it's a bill that contains "the entire setup, groundwork and infrastructure to move from cash to digital currency."October 22 at 2:00 AM | Goldco Precious Metals (Ad)NGM Biopharmaceuticals Advances in Cancer Cachexia Treatment with NGM120 StudyJune 27, 2025 | tipranks.comBiosion, Inc. Appoints Kedan Lin, Ph.D., as Chief Development Officer and President of Biosion USFebruary 19, 2025 | finance.yahoo.comNGM Bio Announces Appointment of Wendy Yeh, M.D. as Chief Medical OfficerFebruary 4, 2025 | finance.yahoo.comNGM Bio and KdT Ventures Enter into Worldwide License Agreement for NGM313, a Phase 2-ready FGFR1c/ß-Klotho Agonist Drug CandidateDecember 19, 2024 | tmcnet.comNGM Bio and KdT Ventures Enter into Worldwide License Agreement for NGM313, a Phase 2-ready FGFR1c/β-Klotho Agonist Drug CandidateDecember 19, 2024 | finance.yahoo.comSee More Headlines NGM Stock Analysis - Frequently Asked Questions How were NGM Biopharmaceuticals' earnings last quarter? NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) issued its earnings results on Thursday, November, 4th. The company reported ($0.37) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by $0.03. The business had revenue of $18.58 million for the quarter, compared to the consensus estimate of $18.90 million. NGM Biopharmaceuticals had a negative trailing twelve-month return on equity of 77.85% and a negative net margin of 3,223.34%. When did NGM Biopharmaceuticals IPO? NGM Biopharmaceuticals (NGM) raised $100 million in an initial public offering (IPO) on Thursday, April 4th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Cowen acted as the underwriters for the IPO. What other stocks do shareholders of NGM Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that NGM Biopharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Adobe (ADBE), Advanced Micro Devices (AMD), Broadcom (AVGO), CymaBay Therapeutics (CBAY) and PayPal (PYPL). Company Calendar Last Earnings11/04/2021Today10/22/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:NGM CIK1426332 Webwww.ngmbio.com Phone(650) 243-5555FaxN/AEmployees138Year Founded1998Profitability EPS (Trailing Twelve Months)($1.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$142.38 million Net Margins-3,223.34% Pretax Margin-3,223.34% Return on Equity-77.85% Return on Assets-67.76% Debt Debt-to-Equity RatioN/A Current Ratio7.79 Quick Ratio7.79 Sales & Book Value Annual Sales$4.42 million Price / Sales29.10 Cash FlowN/A Price / Cash FlowN/A Book Value$1.80 per share Price / Book0.86Miscellaneous Outstanding Shares83,462,000Free Float53,499,000Market Cap$128.53 million OptionableOptionable Beta1.27 Social Links The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:NGM) was last updated on 10/22/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredWhat Wall Street Won’t Say Out LoudDiscover the 7 key indicators before everyone else doesAmerican Alternative | SponsoredCould this strange machine change society forever?A mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredTrump cannot stop this trainThe Nobel Committee just confirmed what free-market thinkers have long argued — that true wealth isn’t built t...Porter & Company | SponsoredElon Musk is on the lineElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | SponsoredThe End of Elon Musk…?While headlines point to collapsing sales and fading tax credits, tech analyst Jeff Brown says Tesla is on the...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NGM Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NGM Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.